Product: Helioxanthin derivative 5-4-2
BRCA2 Antibody Summary
| Immunogen |
Synthetic peptide corresponding to amino acids 2587 – 2601 of the human BRCA2 precursor, conjugated to Keyhole Limpet Haemocyanin. Peptide sequence: LIPSNDGKAGKEEFY
|
| Clonality |
Polyclonal
|
| Host |
Rabbit
|
| Gene |
BRCA2
|
| Purity |
Protein G purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
|
| Application Notes |
For IHC-P: This product requires antigen retrieval using heat treatment prior to staining of paraffin sections.
|
|
| Publications |
|
Reactivity Notes
Human. Predicted cross-reactivity based on sequence identity: Cat, Chimpanzee, Dog, Horse, Mouse, Rat, Rhesus Monkey.
Packaging, Storage & Formulations
| Storage |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
|
| Buffer |
Phosphate buffered saline
|
| Preservative |
0.09% Sodium Azide
|
| Concentration |
5.0 mg/ml
|
| Purity |
Protein G purified
|
Alternate Names for BRCA2 Antibody
- BRCA1/BRCA2-containing complex, subunit 2
- BRCA2
- BRCC2
- breast and ovarian cancer susceptibility gene, early onset
- breast cancer 2 tumor suppressor
- breast cancer 2, early onset
- breast cancer susceptibility protein BRCA2
- breast cancer type 2 susceptibility protein
- BROVCA2
- FACD
- FAD
- FAD1
- FANCB
- FANCD
- FANCD1Fanconi anemia, complementation group D1
- Fanconi anemia group D1 protein
- GLM3
- PNCA2
Background
BRCA 2 is localized to chromosome 13q12 – q13. Loss of heterozygosity of 13q is observed in 25% of sporadic breast tumors, which indicates that BRCA 2 might be a tumor suppressor gene. BRCA 2 confers only a low ovarian cancer risk. Reportedly, in MCF-10F (normal breast epithelial cell line) and MCF-7 (breast cancer cell line) cells the expression of BRCA 2 RNA lowers in G0 and early G1 phases then gets up-regulated at the G1 / S phase junction.